罗海彬博士、教授、博士生导师，
药学院副院长，中山大学首届“优秀青年教师”培养计划入选者，主要从事药物化学（药物分子设计）、结构生物学和计算化学方面的研究，在基于靶标结构的药物分子设计、合成、活性测定及晶体结构方面的研究具有特色。多年来从事抗老年性痴呆、哮喘、糖尿病、男性性功能障碍等药物的靶标结构生物学和发现研究，重点构建基于靶标磷酸二酯酶（PDE）和醛糖还原酶(AR)的药物筛选体系，并进行相关的药物分子设计、有机合成和作用机制研究。2000年以来, 在Cell、Plant Cell、J Med Chem、Org Lett、J Chem Inf Model、J Chromatogr A、Biochem Pharm、PLoS ONE、J Phys Chem B、FEBS Lett、J Struct Biol、J Chromatogr B、Bioorg Med Chem Lett等国内外重要期刊上共发表80多篇论文。姓 名：罗海彬性 别：男民 族：汉出生年月：1977.09籍 贯：福建省连城县学历：哲学博士地址：广州大学城外环东路132号中山大学药学院1、1995.09 – 1999.07 厦门大学化学系 本科2、1999.09 – 2002.07 厦门大学化学系硕士3、2002.10 – 2005.10 香港浸会大学化学系 博士4、2005.11 – 2006.12 香港浸会大学生物系和化学系 博士后5、2006.12 –2011.12中山大学药学院，副教授（百人计划引进）6、2008.07 - 2008.10 美国弗吉尼亚大学医学院 访问学者7、2011.12 - 中山大学药学院，教授8、2012.06 - 2014.04 中山大学药学院，院长助理9、2014.04 -中山大学药学院，副院长计算机辅助药物分子设计重要药物靶标的结构生物生物学计算机在药学中的应用计算化学（量子化学、动力学模拟、化学计量学）生物大分子的动力学模拟 (核酸、蛋白质和生物膜)1、选择性识别磷酸二酯酶PDE9的嘧啶酮类衍生物：设计、合成与分子机制研究，国家自然科学基金，65万，2014.01-207.12，主持　　2、磷酸二酯酶PDE9特异性配体的识别机制 - 计算模拟和生物化学研究，国家自然科学基金，25万，2012.01-2014.12，主持　　3、基于靶标磷酸二酯酶结构的先导物筛选及其临床前研究，广东省自然科学基金团队项目，50万，2011.10-2016.10，主持　　4、防治阿尔茨海默症1类新药LW33及衍生物的临床前研究（初步数据），广州开发区中山大学生物工业研究院，48万，2013.01-2014.08，主持　　5、磷酸二酯酶PDE9高选择性抑制剂的设计和构效关系研究，教育部博士点博导基金，12万，2014.01-2016.12，主持　　6、磷酸二酯酶PDE9高选择性抑制剂的设计和构效关系研究，广东省自然科学基金，5万，2013.10-2015.09，主持　　7、抗哮喘磷酸二酯酶PDE4特异性抑制剂－中药枇杷叶的有效成分筛选及作用机理研，究广州市科技计划，8万，2014.04-2016.0，3主持　　8、防治阿尔茨海默症I类新药LW33的临床前研究，中山大学"创新药物研发专项"，80万，2013.06-2017.05，主持在Cell、Org Lett、J Med Chem、J Chem Inf Model、J Chromatogr A、Biochem Pharm、FEBS Lett、J Struct Biol、Bioorg Med Chem Lett 等国内外杂志发表论文80多篇（*表示为论文通讯作者）。[1] Meng, F.; Hou, J.; Shao, Y. X.; Wu, P. Y.; Huang, M.; Zhu, X.; Cai, Y. H.; Li, Z.; Xu, J.; Liu, P. Q.;  Wan, Y. Q.*; Ke, H*. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.  , 55(19): 8549-8558. PMID: 22985069.[2] Huang, Y.Y.; Li, Z.; Cai, Y.H.; Feng, L.J.; Wu, Y.; Li, X.;  The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: A modeling study.  , , 3044-3053. PMID: 24180640.[3] Li, Z.; Cai, Y.H.; Cheng, Y.K.; Lu, X.; Shao, Y.X.; Li, X.; Liu, M.; Liu, P.; Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay.  ,53, 972-981. PMID: 23517293.[4] Park, S.J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Ke, H.M.; Rehmann, H.; Taussig, R.; Brown, A.L.; Kim, M.K.; Beaven, M.A.; Burgin, A.B.; Manganiello, V.; Chung, J.H.* Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP .  , 148(3): 421-433. PMID: 22304913.[5] Shang, N.N.; Shao, Y.X.; Cai, Y.H.; Guan, M.; Huang, M.; Cui, W.; He, L.; Yu, Y.J.; Huang, L.; Li, Z.; Bu, X. Z.*; Ke, H.*;  Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure.  , : 86-98. PMID:24565909[6] Liu, X.(#); ; Huang, Y.Y.; Bao, J.M.; Tang, G.H.; Chen, Y.Y.; Wang, J.; Yin, S. Selaginpulvilins A-D, New phosphodiesterase-4 inhibitors with an unprecedented skeleton from . , , 282-285. PMID: 24328835.[7] Lin, T.T.; Huang, Y.Y.; Tang, G.H.; Cheng, Z.B.; Liu, X.;  Yin, S.* Prenylated Coumarins: Natural Phosphodiesterase-4 Inhibitors from .  , : 955-962. PMID:24597921[8] Liu, Y.N.; Huang, Y.Y.; Bao, J.M.; Cai, Y.H.; Guo, Y.Q.; Liu, S.N.; Yin, S.* Natural phosphodiesterase-4 (PDE4) inhibitors from .  , : 177-182. PMID:24594242[9] Sun, Z.-H.; Cai, Y.-H.; Fan, C.-Q.; Tang, G.-H.;  Yin, S. Six new tetraprenylated alkaloids from the south china sea Gorgonian .  , , 672-681. PMID:24473168[10] Zhao, P.; Chen, S.K.; Cai, Y.H.; Lu, X.; Li, Z.; Cheng, Y.K.; Zhang, C.; Hu, X.; He, X.*;  The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay. . , 1834(10): 2089-2096. PMID: 23871879.[11] Zhong, J.; Huang, Y.; Ding, W.; Wu, X.; Wan, J.*;  Chemical constituents of Aloe barbadensis Miller and their inhibitory effects on phosphodiesterase-4D. Fitoterapia. 2013, 91:159-165. PMID: 24028970.[12] Li, Y.P.; Weng, X.; Ning, F.X.; Ou, J.B.; Hou, J.Q.;  Li, D.; Huang, Z.S.; Huang, S.L.*; Gu, L.Q. 3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method. , 41: 61-67. PMID: 23500628.[13] Luo, Z.; Sheng, J.; Sun, Y.; Lu, C.; Yan, J.; Liu, A.;  Huang, L.*; Li, X*. Synthesis and evaluation of multi-target-directed ligands against alzheimer's disease based on the fusion of donepezil and ebselen. , 56(22): 9089-9099. PMID: 24160297.[14] Lu, C.; Guo, Y.; Yan, J.; Luo, Z.;  Yan, M.; Huang, L.*; Li, X. * Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease.  , 56(14): 5843-5859. PMID: 23799643.[15] Chen, S.-K.; Zhao, P.; Shao, Y.-X.; Li, Z.; Liu, M.; Zhang, C.X.; Liu, P.Q.; He, X.X. *; *; Hu, X.P. Moracin M from . is a natural  inhibitor.  , 22: 3261–3264. PMID:22483586[16] Zheng, X.H.; Shao, Y.X.; Li, Z.; Liu, M.; Bu, X.Z.; ; Hu, X.P.; Quantitative structure-retention relationship of curcumin and its analogues.  , 35: 505-512. PMID:22282411[17] Shao, Y.X; Zhao, P.; Li, Z.; Liu, M.; Liu, P.Q.; Huang, M.;  The molecular basis for the inhibition of human cytochrome P450 1A2 by oroxylin and wogonin.  , 41: 297-306.[18] Zheng, X.H.; Zhang, L.P.; Zhai, J; Chen, Y.Y.; *; Hu, X.P. *.The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase.  2012, 586: 55-59. PMID:22228220[19] Hou, J.Q.; Chen, S.B.; Tan, J.H.; Li, D.; Gu, L.Q.; Huang, Z.S. New insights from molecular dynamic simulation studies of the multiple binding modes of a ligand with G-quadruplex DNA. . , 26(12):1355-1368.[20] Mo, S.L.; Liu, W. F.; Chen, Y.;  Sun, L.B.; Chen, X.W.; Zhou, Z.W.; Sneed, K.B.; Li, C.G.; Du, Y.M.; Liang, J.; Zhou, S.F. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis.  , 15(1): 36-80. PMID:21846324[21] Mo, S.L.; Liu, W.F.; Li, C.G.; Zhou, Z.W.; , Chew, H.; Liang, J.; Zhou S.F. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.  , 13(9): 1640-1704.[22] Wang, N.; Wang, Z.Y.; Mo, S.L.; Loo, T.Y.; Wang, D.M.;  Yang, D.P.; Chen, Y.L.; Shen, J.G.; Chen, J. P. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. , 134(3): 943-955.[23] Hou, J.; Wojciechowska, K.; Zheng, H.; Chruszcz, M.; Cooper, D.R.; Cymborowski, M.; Skarina, T.; Gordon, E.; Savchenko, A,; Minor, W. Structure of a short-chain dehydrogenase/reductase from Bacillus anthracis.  , 68(Pt 6): 632-637.[24] Fang, J.; Huang, D.; Zhao, W.; Ge, H.;Xu, J. *. A new protocol for predicting novel GSK-3 beta ATP competitive inhibitors. , 51: 1431-1438.[25] Hou, J.; Xu, J.; Liu, M.; Zhao, R.; ; Ke, H.*. Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine.  , 6. e18092.[26] Liu, M.; Yuan, M.G.; Li, Z.; Cheng, Y.K.; ; Hu, X.P.*. Structural investigation into the inhibitory mechanisms of indomethacin and its analogues towards human glyoxalase I. , 21: 4243-4247.[27] Chen, Y.Y.; Chen, G.W.; * Molecular insight into the inhibitory mechanism of galangin towards human cytochrome P450 1A2. A modeling study. , 8: 216-222.[28] Xu, J., Lu, Y.; Shen, W.; et al., Homology modeling of alpha-glucosidase and its interactions with andrograpolide derivatives. , 8: 440-451.[29] Lu, S.-Y.; Jiang, Y.-J.; Zou, J.;.et al., Insight into analysis of interactions of GW9508 to wild-type and H86F and H137F GPR40: A combined QM/MM study and pharmacophore modeling.  , 29: 818-825.[30] Wei, H.; Yin, L.; et al., Structural influence of chiral tertiary aminonaphthol ligands on the asymmetric phenyl transfer to aromatic aldehydes.  , 23: 222-227.[31] Chen, S.B.; Tan, J.H.; Ou, T.M.; Huang, S.L.; An, L.K.; et al., Pharmacophore-based discovery of triaryl-substituted imidazole as new telomeric G-quadruplex ligand.  , 21: 1004-1009.[32] Hou, J.Q.; Tan, J.H.; Wang, X,-X.; Chen, S.B; Huang, S.Y.; Yan, J.W.; Chen, S.H.; Ou, T.M.; et al., Impact of planarity of unfused aromatic molecules on G-quadruplex binding: Learning from isaindigotone derivatives. , 9: 6422-6436.[33]  Zheng, H.-P.; et al. Crystal structure and molecular modeling study of N-carbamoylsarcosine amidase Ta0454 from .  , 169: 304-311.[34] He, L; He, F.; Bi, H.C.; Li, J.K.; Zeng, S.; *; Huang, M. Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations.  . 20: 6008-6012.[35] Liu, M.; He, L.; Hu, X.P.; Liu, P.Q.; * 3D-QSAR, homology modeling, and molecular docking studies on spiropiperidines analogues as agonists of nociceptin/orphanin FQ receptor. , 20: 7004-7010.[36] Liu, M.; Yuan, M.G.; Luo, M.X.; Bu, X.Z.; *; Hu, X.P.* Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis.  147: 28-34.[37] Xu, J.; Huang, S.; et al., QSAR studies on andrographolide derivatives as alpha-glucosidase inhibitors., 11: 880-895.[38] Hou, J.-Q.; Chen, S.B.; Tan, J.-H.; Ou, T.M.;  et al. New insights into the structures of ligand-quadruplex complexes from molecular dynamics simulations.  , 114: 15301–15310.[39] Yan, J.B.; Zhang, C; Gu, M.; Bai, Z.Y.; Zhang, W.G.; Qi, T.C.; Cheng, Z.W.; Peng, W.;  et al. The arabidopsis coronatine insensitive1 protein is a jasmonate receptor. 21: 2220-2236.[40] Tan, J. H.; Ou, T. M.; Hou, J. Q.; Lu, Y. J.; Huang, S. L.;  et al. Isaindigotone derivatives: a new class of highly selective ligands for telomeric g-quadruplex DNA.  , 9: 2825-2835.[41] Lao, J.; Zhang, X.; Wang, J.; Li, X.M.; Yan, M.;  et al. The effect of hydrogen bond donors in asymmetric organocatalytic conjugate additions.  , 20: 2818-2822.[42]  Zheng, C.Q.; Cheng, Y.-K. Is phospholipid-saturated alkyl column a convenient replacement for immobilized-artificial-membrane?  , 1176: 100-106.[43]  Zheng, C.Q.; Cheng, Y.-K. Complex retention behavior of pyrimidines on biomembrane-mimicimmobilized-artificial-membranephase.  , 853: 114-122.[44]  Zheng, C.Q.; Cheng, Y.-K. The retention properties of nucleobases in alkyl C-/C- and IAM- chromatographic systems in relation to log P. , 847: 245-261.[45] Chan, W.;  Zhang, Y. F.; Cheng, Y.-K.; Cai, Z. W. Investigation of the Metabolism and Reductive Activation of Carcinogenic Aristolochic Acids in Rats. ,35: 866-874.[46] Leng, X.B.; Choi, C.–F.;  Cheng, Y.-K.; Ng, D.K.P. Host-guest interactions of 4-carboxyphenoxy phthalocyanines and cyclodextrins in aqueous media. , 9: 2497-2500.[47] Lian, Z.X.; Cai, J.W.; Chen, C.H.;  Linear silver isonicotinamide complex extended by arenedisulfonate via hydrogen bonds and weak Ag-O interactions.  , 9: 319-327.[48] Sun, X. H.; Li, W. Y.; Xia, P. F.;  et al., Phenyl-calix[4]arene-based fluorescent sensors: Cooperative binding for carboxylates.  , 72: 2419-2426.[49] Leung, K.W.; Yung, K.K.L.; Mak, N.K.; Yue, P.Y.K.;  et al., Angiomodulatory and neurological effects of ginsenosides. 2007, 14(12): 1371-1380.[50]  Cheng, Y.-K. A comparative study of void volume markers inimmobilized-artificial-membraneand reversed-phase liquid chromatography  , 1103: 356-361. 中山大学